In addition, a prospective study of patients with metastatic melanoma and renal cell carcinoma found that elevated pre-treatment serum VEGF and fibronectin are inversely correlated with the response rate to HD-IL-2 [79]. Here, VEGFA is linked to metastatic melanoma.